Advertisement

Molecular Imaging and Targeted Therapy for Malignant Melanoma

  • Bin Zhang
Chapter

Abstract

Malignant melanoma is a tumor produced by the melanocytes of the skin and other organs. Skin melanoma shows a significant change in pigmented skin lesions for months or years. Most malignant melanoma occurs in adults. Although the incidence of malignant melanoma is low, its malignant degree is high, the metastasis is early, and the mortality is high, so early diagnosis and early treatment are very important.

References

  1. 1.
    Dummer R, Hauschild A, Lindenblatt N et al (2015) Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(S5):v126–v132PubMedCrossRefGoogle Scholar
  2. 2.
    Dummer R, Hauschild A, Guggenheim M et al (2010) Melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(S5):v194–v197PubMedCrossRefGoogle Scholar
  3. 3.
    Garbe C, Peris K, Hauschild A et al (2012) Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline—update 2012. Eur J Cancer 48(15):2375–2390PubMedCrossRefGoogle Scholar
  4. 4.
    Brugnara S, Sicher M, Bonandini EM et al (2018) Treatment with combined dabrafenib and trametinib in BRAFV600E-mutated metastatic malignant melanoma: a case of long-term complete response after treatment cessation. Drugs Context 7:212515PubMedPubMedCentralGoogle Scholar
  5. 5.
    Flaherrty K, Robert C, Hersey P et al (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367:107–114CrossRefGoogle Scholar
  6. 6.
    Kirkwood J, Bastholt L, Robert C et al (2012) Phase II, open-label, randomized trial of the MEK 1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res 18:555–567PubMedCrossRefGoogle Scholar
  7. 7.
    Mahoney KM, Freeman GJ, McDermott DF (2015) The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma. Clin Ther 37(4):764–782PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Algazi AP, Tsai KK, Shoushtari AN et al (2016) Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer 122:3344–3353PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Schwenzer NF, Pfannenberg AC (2015) PET/CT, MR, and PET/MR in lymphoma and melanoma. Semin Nucl Med 45:322–331PubMedCrossRefGoogle Scholar
  10. 10.
    Krug B, Crott R, Lonneux M et al (2008) Role of PET in the initial staging of cutaneous malignant melanoma: systematic review. Radiology 249(3):836–844PubMedCrossRefGoogle Scholar
  11. 11.
    Xing Y, Bronstein Y, Ross MI et al (2011) Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst 103(2):129–142PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Veithaibach P, Vogt FM, Jablonka R et al (2009) Diagnostic accuracy of contrast-enhanced FDG-PET/CT in primary staging of cutaneous malignant melanoma. Eur J Nucl Med Mol Imaging 36(6):910–918CrossRefGoogle Scholar
  13. 13.
    Singh B, Ezziddin S, Palmedo H et al (2008) Preoperative 18F-FDG-PET/CT imaging and sentinel node biopsy in the detection of regional lymph node metastases in malignant melanoma. Melanoma Res 18(5):346–352PubMedCrossRefGoogle Scholar
  14. 14.
    Li DL, Li HS, Wang QS et al (2008) Clinical value of 18F-FDG PET/CT in detection of malignant melanoma. Chin J Nucl Med 28(5):295–298Google Scholar
  15. 15.
    Hu YY, Lin XP, Liang PY et al (2009) Application of 18F-FDG PET/CT in diagnosis and staging of malignant melanoma. Chin J Med Imag Technol 25(4):685–688Google Scholar
  16. 16.
    Danielsen M, Hojgaard L, Kjar A et al (2013) Positron emission tomography in the follow-up of cutaneous malignant melanoma patients: a systematic review. Am J Nucl Med Mol Imaging 4(1):17–28PubMedPubMedCentralGoogle Scholar
  17. 17.
    Wieder HA, Tekin G, Rosenbaum-krumme S et al (2013) 18FDG-PET to assess recurrence and long term survival in patients with malignant melanoma. Nuklearmedizin 52(5):198–203PubMedCrossRefGoogle Scholar
  18. 18.
    Bastiaannet E, Hoekstra OS, de Jong JR et al (2012) Prognostic value of the standardized uptake value for 18F-fluorodeoxyglucose in patients with stage IIIB melanoma. Eur J Nucl Med Mol Imaging 39(10):1592–1598PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Rueth NM, Xing Y, Chiang YJ et al (2014) Is surveillance imaging effective for detecting surgically treatable recurrences in patients with melanoma? A comparative analysis of stage-specific surveillance strategies. Ann Surg 259(6):1215–1222PubMedCrossRefGoogle Scholar
  20. 20.
    Bronstein Y, Ng CS, Rohren E et al (2012) PET/CT in the management of patients with stage IIIC and IV metastatic melanoma considered candidates for surgery:evaluation of the additive value after conventional imaging. Am J Roentgenol 198(4):902–908CrossRefGoogle Scholar
  21. 21.
    Harris MT, Berlangieri SU, Cebon JS et al (2005) Impact of 2-deoxy-2[F-18] fluoro-D-glucose positron emission tomography on the management of patients with advanced melanoma. Mol Imaging Biol 7(4):304–308PubMedCrossRefGoogle Scholar
  22. 22.
    Willson JK, Albert DM, Diener-West M et al (2001) Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol 119(5):670–676CrossRefGoogle Scholar
  23. 23.
    Strobel K, Bode B, Dummer R et al (2009) Limited value of 18F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma. Eur J Nucl Med Mol Imaging 36(11):1774–1782PubMedCrossRefGoogle Scholar
  24. 24.
    Klingenstein A, Haug AR, Nentwich MM et al (2010) Whole-body F-18-fluoro-2- deoxyglucose positron emission tomography/computed tomography imaging in the follow-up of metastatic uveal melanoma. Melanoma Res 20(6):511–516PubMedCrossRefGoogle Scholar
  25. 25.
    Francken AB, Fulham MJ, Millward MJ et al (2006) Detection of metastatic disease in patients with uveal melanoma using positron emission tomography. Eur J Surg Oncol 32(7):780–784PubMedCrossRefGoogle Scholar
  26. 26.
    Servois V, Mariani P, Malhaire C et al (2010) Preoperative staging of liver metastases from uveal melanoma by magnetic resonance imaging (MRI) and fluorodeoxyglucose-positron emission tomography (FDG-PET). Eur J Surg Oncol 36(2):189–194PubMedCrossRefGoogle Scholar
  27. 27.
    Orcurto V, Denys A, Voelter V et al (2012) 18F-fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging in patients with liver metastases from uveal melanoma: results from a pilot study. Melanoma Res 22(1):63–69PubMedCrossRefGoogle Scholar
  28. 28.
    Wolchok JD, Hoos A, O’Day S et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15(23):7412–7420PubMedCrossRefGoogle Scholar
  29. 29.
    Flaherty KT, Puzanov I, Kim KB et al (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363(9):809–819PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Strobel K, Skalsky J, Steinert HC et al (2007) S-100B and FDG-PET/CT in therapy response assessment of melanoma patients. Dermatology 215(3):192–201PubMedCrossRefGoogle Scholar
  31. 31.
    Hofman MS, Constantinidou A, Acland K et al (2007) Assessing response to chemotherapy in metastatic melanoma with FDG PET: early experience. Nucl Med Commun 28(12):902–906PubMedCrossRefGoogle Scholar
  32. 32.
    Geven EJ, Evers S, Nayak TK et al (2015) Therapy response monitoring of the early effects of a new BRAF inhibitor on melanoma xenograft in mice: evaluation of F-FDG-PET and F-FLT-PET. Contrast Media Mol Imaging 10(3):203–210PubMedCrossRefGoogle Scholar
  33. 33.
    Guerreschi P, Scalbert C, Qassemyar A et al (2013) Patient-derived tumor xenograft model to guide the use of BRAF inhibitors in metastatic melanoma. Melanoma Res 23:373–380PubMedCrossRefGoogle Scholar
  34. 34.
    O’Day S, Pavlick A, Loquai C et al (2011) A randomised, phase II study of intetumumab, an anti-alphav-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer 105(3):346–352PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Kim KB, Prieto V, Joseph RW et al (2012) A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma. Melanoma Res 22(4):294–301PubMedCrossRefGoogle Scholar
  36. 36.
    Mena E, Owenius R, Turkbey B et al (2014) [18F]fluciclatide in the in vivo evaluation of human melanoma and renal tumors expressing αvβ 3 and α vβ 5 integrins. Eur J Nucl Med Mol Imaging 41(10):1879–1888PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Qin C, Liu H, Chen K et al (2014) Theranostics of malignant melanoma with 64CuCl2. J Nucl Med 55(5):812–817PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Wang Y, Li M, Zhang Y et al (2017) Detection of melanoma metastases with PET-comparison of 18F-5-FPN with 18F-FDG. Nucl Med Biol 50:33–38PubMedCrossRefGoogle Scholar
  39. 39.
    Xie L, Yui J, Fujinaga M et al (2014) Molecular imaging of ectopic metabotropic glutamate 1 receptor in melanoma with a positron emission tomography radioprobe 18F-FITM. Int J Cancer 135(8):1852–1859PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. and Shanghai Jiao Tong University Press 2019

Authors and Affiliations

  • Bin Zhang
    • 1
  1. 1.The First Affiliated Hospital of Soochow UniversitySuzhouP. R. China

Personalised recommendations